A Phase 4 interventional study of insulin detemir and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-17.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 2.
Among the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 2 that started in 2011, is one of 23 in phase 4, and was the 37th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18+
By country, each count listing its studies:
Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 130 across the 43 interventional studies. Of the 40 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 43 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 320th largest by enrollment of the 430 interventional ones that give a count, is one of 23 that started in 2011, is one of 75 in phase 4, and was the 239th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in Chinese patients with type 2 diabetes.
The trial adopts a group sequential design, where the analysis of the primary efficacy endpoint will be performed at the interim analysis, in addition to the final formal analysis. The decision to continue or stop the trial will be based on the result of the interim analysis.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 58 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin detemir · Drug: insulin aspart · Drug: metformin
Drug: insulin NPH · Drug: human soluble insulin · Drug: metformin
Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment
Mean value of 8-point PG was the arithmetic mean of all 8 time-instant PG values of the 8-point PG profile.
Time frame: Week 0, week 2
Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment
The FPG referred to pre-breakfast plasma glucose.
Time frame: Week 0, week 2
Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment
The mean 2hPPG was derived from the 8-point PG profile as the mean value of the available 120 minutes after each meal.
Time frame: Week 0, week 2
Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment
The mean value of pre-lunch, pre-dinner and bedtime PG was derived from the 8-point PG profile measured before lunch, dinner and bedtime.
Time frame: Week 0, week 2
Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment
Time frame: Week 2
Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment
Time frame: Week 2
Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment
FPG target was \< 6.0 mmol / L, 2hPPG target was \< 8.0 mmol / L.
Time frame: Week 2
Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment
FPG target was \< 6.0 mmol / L. Nocturnal hypoglycaemia was defined as a hypoglycaemic episode happened between 00:01 and 05:59 a.m. (both included).
Time frame: Week 2
Change From Baseline in Fructosamine After Two Weeks of Treatment
Time frame: Week 0, week 2
Incidence of Hypoglycaemic Episodes
All events summarized were treatment emergent hypoglycaemic events. Hypoglycaemic episodes were summarized based on the ADA classification and also according to an additional definition. Severe hypoglycemia: ADA definition. Minor hypoglycaemic episode: an episode with symptoms with confirmation by plasma glucose (PG) \< 3.1 mmol/l (56 mg/dl) and was handled by the subject himself/herself, or any asymptomatic PG value \< 3.1 mmol/l (56 mg/dl). A hypoglycaemia episode was defined as nocturnal if the time of onset was between 00:01 and 05:59 a.m. (both included), otherwise it was diurnal.
Time frame: Weeks 0-2
A total of 6 centres in China participated.
| Milestone | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Started | 29 | 29 |
| Completed | 29 | 27 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Mean value of 8-point PG was the arithmetic mean of all 8 time-instant PG values of the 8-point PG profile.
| mmol/L | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment | -2.84 ± 0.27 | -2.80 ± 0.28 |
The FPG referred to pre-breakfast plasma glucose.
| mmol/L | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) After Two Weeks of Treatment | -2.22 ± 0.34 | -2.29 ± 0.35 |
The mean 2hPPG was derived from the 8-point PG profile as the mean value of the available 120 minutes after each meal.
| mmol/L | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose (2hPPG) of 3 Meals After Two Weeks of Treatment | -4.00 ± 0.39 | -3.47 ± 0.40 |
The mean value of pre-lunch, pre-dinner and bedtime PG was derived from the 8-point PG profile measured before lunch, dinner and bedtime.
| mmol/L | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Change From Baseline in Mean Value of Pre-lunch, Pre-dinner and Bedtime PG After Two Weeks of Treatment | -2.47 ± 0.38 | -2.87 ± 0.38 |
| percentage (%) of subjects | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Percentage of Subjects Achieving FPG < 6.0 mmol / L After Two Weeks of Treatment | 48.3 | 48.3 |
| percentage (%) of subjects | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L After Two Weeks of Treatment | 41.4 | 34.5 |
FPG target was \< 6.0 mmol / L, 2hPPG target was \< 8.0 mmol / L.
| percentage (%) of subjects | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Percentage of Subjects Achieving Both FPG and 2hPPG Targets After Two Weeks of Treatment | 20.7 | 20.7 |
FPG target was \< 6.0 mmol / L. Nocturnal hypoglycaemia was defined as a hypoglycaemic episode happened between 00:01 and 05:59 a.m. (both included).
| percentage (%) of subjects | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia After Two Weeks of Treatment | 41.4 | 34.5 |
| Umol/L | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| Change From Baseline in Fructosamine After Two Weeks of Treatment | -31.0 ± 5.37 | -23.7 ± 5.50 |
All events summarized were treatment emergent hypoglycaemic events. Hypoglycaemic episodes were summarized based on the ADA classification and also according to an additional definition. Severe hypoglycemia: ADA definition. Minor hypoglycaemic episode: an episode with symptoms with confirmation by plasma glucose (PG) \< 3.1 mmol/l (56 mg/dl) and was handled by the subject himself/herself, or any asymptomatic PG value \< 3.1 mmol/l (56 mg/dl). A hypoglycaemia episode was defined as nocturnal if the time of onset was between 00:01 and 05:59 a.m. (both included), otherwise it was diurnal.
| events | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| All events | 22 | 54 |
| Severe | 0 | 0 |
| Nocturnal | 4 | 11 |
| Diurnal | 18 | 43 |
| Minor | 2 | 11 |
Collected over The adverse events were collected in a timeframe of 2 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Detemir + Insulin Aspart ± Metformin | — | 0/29 (0%) | 0/29 (0%) |
| Insulin NPH + Human Soluble Insulin ± Metformin | — | 0/29 (0%) | 2/29 (6.9%) |
| Event | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin |
|---|---|---|
| upper restiratory tract infectionInfections and infestations | 0/29 | 2/29 |
| Age, Continuous(years) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Mean | 57.6 ± 10.2 | 55.8 ± 9.8 | 56.7 ± 9.9 |
| Sex: Female, Male(Participants) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Female | 14 | 15 | 29 |
| Male | 15 | 14 | 29 |
| Race (NIH/OMB)(Participants) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 29 | 29 | 58 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height(cm) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Mean | 164.2 ± 8.5 | 164.2 ± 8.4 | 164.2 ± 8.4 |
| Weight(kg) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Mean | 70.9 ± 13.1 | 66.5 ± 9.0 | 68.7 ± 11.4 |
| Body mass index (BMI)(kg/m^2) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Mean | 26.09 ± 3.13 | 24.63 ± 2.67 | 25.36 ± 2.98 |
| Pre-trial treatment of oral antidiabetic drug(participants) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| Acarbose | 9 | 10 | 19 |
| Gliclazide | 0 | 3 | 3 |
| Glimepiride | 2 | 4 | 6 |
| Metformin | 13 | 8 | 21 |
| Metformin hydrochloride | 2 | 3 | 5 |
| Repaglinide | 2 | 2 | 4 |
| Pre-trial insulin treatment(participants) | Insulin Detemir + Insulin Aspart ± Metformin | Insulin NPH + Human Soluble Insulin ± Metformin | Total |
|---|---|---|---|
| basal insulin (once daily) | 6 | 7 | 13 |
| premixed insulin (twice daily) | 23 | 22 | 45 |
4 further baseline measures are reported on the registry.
The record gives a start of Nov 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Detemir · Insulin Aspart